| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 5, Issue 3 341-347, Copyright © 1994 by American Association of Cancer Research
ARTICLES |
BM Burgering, E Freed, L van der Voorn, F McCormick and JL Bos
Laboratory for Physiological Chemistry, Utrecht, The Netherlands.
Stimulation with platelet-derived growth factor (PDGF) results in the association of several SH2 domain-containing proteins with the activated PDGF receptor, including GAP, a GTPase-activating protein of p21ras, and phosphatidylinositol-3-kinase (PI-3K). To investigate the role of GAP-PI-3K receptor interaction in p21ras signaling, we have used cell lines expressing mutant PDGF receptors that either are impaired in GAP binding or fail to bind both GAP and PI-3K. In these cell lines, PDGF treatment resulted in activation of extracellular signal-regulated kinase 2 (ERK2), which could be blocked by the expression of a dominant-negative mutant of p21ras (p21ras(asn17)), indicating that these mutations in the PDGF receptor do not abolish p21ras-mediated activation of ERK2. In addition, the PDGF-induced increase in levels of p21rasGTP, as measured either in intact cells or in permeabilized cells, appears to be normal in the cell lines expressing the mutant PDGF receptors. These results indicate that binding of GAP and/or PI-3K to the PDGF receptor is not necessary for PDGF-induced p21ras activation and p21ras-mediated signaling to ERK2. We also show that, in contrast to the activation of ERK2, PDGF-induced GAP and PI-3K interaction with the PDGF receptor are not inhibited by p21ras(asn17) expression, indicating that these interactions do not require p21ras activation.
This article has been cited by other articles:
![]() |
N. Auge, V. Garcia, F. Maupas-Schwalm, T. Levade, R. Salvayre, and A. Negre-Salvayre Oxidized LDL-Induced Smooth Muscle Cell Proliferation Involves the EGF Receptor/PI-3 Kinase/Akt and the Sphingolipid Signaling Pathways Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1990 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suzuki, J. K-Tsuzuku, R. Ajima, T. Nakamura, Y. Yoshida, and T. Yamamoto Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation Genes & Dev., June 1, 2002; 16(11): 1356 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Z. Hossain, A. B. Jagdale, P. Ao, A. Kazlauskas, and A. L. Boynton Disruption of Gap Junctional Communication by the Platelet-derived Growth Factor Is Mediated via Multiple Signaling Pathways J. Biol. Chem., April 9, 1999; 274(15): 10489 - 10496. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-W. Hu, X.-Y. Shi, R. Z. Lin, and B. B. Hoffman Contrasting Signaling Pathways of {alpha}1A- and {alpha}1B-Adrenergic Receptor Subtype Activation of Phosphatidylinositol 3-Kinase and Ras in Transfected NIH3T3 Cells Mol. Endocrinol., January 1, 1999; 13(1): 3 - 14. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |